Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Evaluation of IL-2, IL-6, IL-8 and IL-10 in Malignant Melanoma Diagnostics

RADEK KUCERA, ONDREJ TOPOLCAN, INKA TRESKOVA, JUDITA KINKOROVA, JINDRA WINDRICHOVA, RADKA FUCHSOVA, SARKA SVOBODOVA, VLADISLAV TRESKA, VACLAV BABUSKA, JAROSLAV NOVAK and JIRI SMEJKAL
Anticancer Research June 2015, 35 (6) 3537-3541;
RADEK KUCERA
1Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ONDREJ TOPOLCAN
1Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
INKA TRESKOVA
2Department of Plastic Surgery, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JUDITA KINKOROVA
1Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kinkorovaj@fnplzen.cz
JINDRA WINDRICHOVA
1Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RADKA FUCHSOVA
1Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SARKA SVOBODOVA
1Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VLADISLAV TRESKA
3Department of Surgery, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VACLAV BABUSKA
4Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JAROSLAV NOVAK
1Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JIRI SMEJKAL
1Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Aim: The aim of the present study was to evaluate the usefulness of four interleukins (IL-2, IL-6, IL-8 and IL-10) for melanoma detection and correlate these interleukins with sentinel node metastasis positivity. Patients and Methods: A group of 236 persons was assessed: 175 patients with melanomas and 61 healthy persons. Melanoma patients were divided to four groups according to Breslow score. We determined IL-2, IL-6, IL-8 and IL-10 in each plasma sample. Interleukin plasma levels were assayed using a Human Cytokine Milliplex Map kit. Measurements were performed using the Bio-Plex MAGPIX Multiplex Reader. Plasma samples were collected prior to surgery or any other form of treatment. All melanoma diagnoses were histologically verified. Results: We compared interleukin plasma levels in the healthy group and plasma levels in each Breslow score stage. In the first Breslow score stage, IL-2 (p<0.0001), IL-6 (p=0.0004) and IL-10 (p<0.0001) were positive. In the second Breslow score, stage IL-2 (p<0.0001), IL-6 (p<0.0001), IL-8 (p=0.0017) and IL-10 (p<0.0001) were positive. By comparing the group of positive and negative sentinel node metastasis, we observed a statistically significant difference in two interleukins: The median of IL-2 levels in the negative group was 5.88 pg/ml compared to 32.57 pg/ml in the positive group (p=0.0005). The median of IL-6 levels in the negative group was 4.80 pg/ml compared to 32.02 pg/ml in the positive group (p=0.0048). Conclusion: Interleukins IL-2, IL-6 and IL-10 are promising biomarkers of early-stage melanoma. IL-2 and IL-6 appear to be prognostic biomarkers.

  • Melanoma
  • interleukin
  • sentinel node
  • Breslow score

Melanoma is one of the most aggressive forms of cancer and potentially lethal if not detected in early stage and treated properly (1). Melanoma is a malignant tumor originating from melanin-producing cells, the melanocytes. Its incidence is increasing worldwide (2). Interleukins (ILs) belong to the broader group of cellular messenger molecules, the cytokines, which allow cells of the immune system to communicate with each other and generate a coordinated, specific response to a target antigen. In tumorigenesis, these cytokines directly stimulate immune effector and stromal cells at the tumor site and enhance tumor cell recognition by cytotoxic effector cells. These findings promoted interleukin research in the diagnostic field. (3).The aim of the present study was to evaluate the utility of four interleukins, interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10), for early melanoma detection and their plasma level correlation with sentinel node metastasis positivity. We also assessed their potential as prognostic factors.

Patients and Methods

Group of patients. This study was conducted between January 2011 and June 2014. We assessed a group of 236 persons: 175 patients (base group) with melanomas and 61 healthy persons (control group). We determined IL-2, IL-6, IL-8 and IL-10 in each plasma sample. For more detailed evaluation, melanoma patients were divided into four groups according to Breslow score. Next, we assessed interleukin plasma levels in the group of melanoma patients in relation to sentinel node metastasis and in the group without metastasis. All melanoma diagnoses were histologically verified.

Plasma samples. Peripheral venous blood was collected using the VACUETTE blood collection system (Greiner Bio-one Company, Kremsmünster, Austria). Plasma was separated by a 10-minute centrifugation step at 1300 xg and immediately frozen to −80°C. Samples were thawed only once, just prior to analyses. Plasma samples were collected at the time of diagnosis, prior to surgery or any other form of treatment.

Methods used. Interleukin plasma levels were assayed using Human Cytokine Milliplex Map kit (Millipore Corporation, Billerica, MA, USA). Measurements were performed using the Bio-Plex MAGPIX Multiplex Reader (Bio-Rad Laboratories, Hercules, CA, USA).

Statistical methods. The SAS 9.2 (Statistical Analysis Software release 9.2; SAS Institute Inc., Cary, NC, USA) was used for all statistical analyses. A summary of statistical findings for age and plasma levels of interleukins is presented. The Wilcoxon test was used to compare distributions of values between the groups of patients in each Breslow score stage with the group of healthy persons. The Wilcoxon test was also used to of the groups with or without sentinel node metastasis.

Results

The patient's characteristics concerning the age of melanoma and control groups are shown in Table I. Table II shows the overview of statistically significant positive interleukins in each Breslow score stage, including the corresponding p-value. A detailed evaluation of interleukin plasma levels in Breslow score stages is shown in Table III. We compared interleukin plasma levels in the healthy proband group and plasma levels of assessed interleukins in each Breslow score stage. In the first Breslow score stage, the results were significantly higher for the following interleukins: IL-2 (median=32.00 pg/ml, p<0.0001) compared to 4.60 pg/ml in the group of healthy probands, IL-6 (median=30.50 pg/ml, p=0.0004) compared to 4.80 pg/ml and IL-10 (median=32.63 pg/ml, p<0.0001) compared to 3.80 pg/ml. In the second Breslow score stage, the results were statistically significantly higher for all assessed interleukins: IL-2 (median=31.88 pg/ml, p<0.0001), IL-6 (median=32.05 pg/ml, p<0.0001), IL-8 (median=17.89 pg/ml, p=0.0017) and IL-10 (median=30.58 pg/ml, p<0.0001) compared to the healthy group. All assessed interleukins were also statistically significantly increased in Breslow score stages three and four. By comparing the group of positive and negative sentinel node metastases we observed a statistically significant change in plasma levels of two interleukins: The median of IL-2 levels in the negative group was 5.88 pg/ml compared to 32.57 pg/ml in the positive group (p=0.0005). The median of IL-6 levels in the negative group was 4.80 pg/ml compared to 32.02 pg/ml in the positive group (p=0.0048).

Discussion

Determination of interleukins started in the late 1980s in connection with the using of interleukins in anticancer therapy (4). The rate of human interleukin release and changes in serum levels of interleukins during oncological treatment have been studied extensively since the 1990s (5). After the year 2000, with the advancing knowledge of cell signaling pathways, the study of interleukin levels reached a new level of importance (6). In the 1990s, research also focused on the role of interleukins in the development of cancer, including melanoma (7, 8).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Age characteristics of patient and control groups.

During the last three decades many studies examined the changes of interleukins in patient groups with cutaneous melanoma in comparison to healthy persons. Clinical results have indicated that early stage melanoma treatment is the most successful. The aim of future research in the field of interleukins as biomarkers for cutaneous melanoma is to find more sensitive and more specific biomarkers for early stage melanoma diagnosis.

In our evaluation we separated the entire melanoma group into four further subgroups using the Breslow scores. The Breslow score is based on measurements of the thickness of the melanoma. As primary tumor thickness increases, there is a significant decrease in survival (9). Currently, there are several systems available for clinical assessment and melanoma diagnostics. However, tumor thickness is one of the most important parameters in melanoma assessment (10).

Another important parameter in the evaluating of biomarkers is age dependence. In our group of patients, we observed that the levels of interleukins were dependent on age. This fact has to be taken into consideration in the evaluation of results. The age of the control group had no statistical significance (p=0.8829) in comparison to the entire group of melanoma patients. When stratifying patients into sub-groups based on the Breslow score, the age distribution of the smaller groups cannot be equal. Therefore, we also tested the statistical significance of the age differences between each group that was formed according to the Breslow score and the group of healthy persons. When the age difference was statistically significant (p<0.05), age adjustment was performed (11).

IL-2 has been used in anticancer therapy for many years. This therapy is effective in patients with melanoma and other types of cancer (12, 13). Other finding shows that the expression of IL-2 in the tumor microenvironment decreases tumor growth (14). Information on the connection between plasma IL-2 levels and cutaneous melanoma prior to treatment remains relatively limited. However, a correlation has been found between elevated IL-2 levels and progression of gastric cancer (15) and non-small cell lung cancer (16). We observed elevated levels of IL-2 in our group of melanoma patients. Levels of IL-2 were statistically significantly higher even from the first stage of the Breslow score. IL-2 was significantly higher in the group of patients with the sentinel nodes metastatic positivity compared to the group of patients without metastasis. Our observation of increased levels of IL-2 looks similar in cases of both gastric and lung cancer. It seems that the plasma levels of IL-2 do not precisely reflect the mechanism of the anti-tumor influence of IL-2 in tissues, but the level correlates with cancer severity.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Positive interleukins and p-values for each Breslow score stage.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Interleukin plasma levels in Breslow score stages.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table IV.

Interleukin plasma levels and sentinel nodes.

Several reports have described an association of serum IL-6 levels and human malignancies (17, 18). The increased plasma levels of IL-6 were described as a negative prognostic factor in patients with cutaneous melanoma measured prior to treatment (19, 20). The literature references regarding metastasis also note that elevated levels in melanoma patients with metastasis indicate a worse prognosis (21, 22) and shorter survival (23). We observed significantly increased levels in melanoma patients starting at the first stage of Breslow score scale. We have also observed significantly higher levels of IL-6 in the group with the sentinel nodes metastatic positivity compared to the group without metastasis. These facts correspond with previous literature findings. High level of IL-6 seems to be a negative prognostic factor.

In several studies IL-8 levels correlated with tumor burden in preclinical models and in patients with several types of cancer including melanoma. Certain authors indicate IL-8 as a potentially useful prognostic marker and as a biomarker for the monitoring of changes after anticancer therapy (24, 25, 26). In our group of patients the plasma IL-8 levels rapidly increased in third and fourth Breslow score stages. In our study, we focused on early stages of cutaneous melanoma. From this point of view IL-8 did not meet our expectations. Neither did we observe any statistically significant difference between the group with the sentinel nodes metastatic positivity and those without metastatic positivity.

In available studies, the plasma levels of IL-10 were elevated in advanced melanoma stages (27, 28). IL-10 was also used as a prognostic marker of anticancer therapy in advanced melanoma stages (29, 30). In our study, the IL-10 levels were significantly elevated from the first Breslow score stage and the elevation continued throughout all four stages. However, we did not observe any difference in the group of patients with the sentinel nodes metastatic positivity compared to the group without metastasis.

Conclusion

Based on Breslow score stage of melanoma, we can conclude that plasma levels of IL-2, IL-6 and IL-10 were significantly elevated, which means that IL-2, IL-6 and IL-10 are good candidate biomarkers of early stage of cutaneous melanoma. Especially, plasma levels of IL-2 and IL-6 were significantly higher in the group with sentinel node metastasis in comparison to the negative group, thus making IL-2 and IL-6 promising prognostic biomarkers.

Acknowledgements

Supported by the Ministry of Health, Czech Republic - conceptual development of research organization (Faculty Hospital in Pilsen - FNPl, 00669806) and IGA grant project NT11017-5/2010.

  • Received February 26, 2015.
  • Revision received March 9, 2015.
  • Accepted March 12, 2015.
  • Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Spatz A,
    2. Stock N,
    3. Batist G,
    4. van Kempen LC
    : The biology of melanoma prognostic factors. Discov Med 10(50): 87-93, 2010.
    OpenUrlPubMed
  2. ↵
    1. Ferlay J,
    2. Steliarova-Foucher E,
    3. Lortet-Tieulent J,
    4. Rosso S,
    5. Coebergh JW,
    6. Comber H,
    7. Forman D,
    8. Bray F
    : Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 49(6): 1374-1403, 2013.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Anestakis D,
    2. Petanidis S,
    3. Kalyvas S,
    4. Nday CM,
    5. Tsave O,
    6. Kioseoglou E,
    7. Salifoglou A
    : Mechanisms and Applications of Interleukins in Cancer Immunotherapy. Int J Mol Sci 16(1): 1691-1710, 2015.
    OpenUrlPubMed
  4. ↵
    1. Bindon C,
    2. Czerniecki M,
    3. Ruell P,
    4. Edwards A,
    5. McCarthy WH,
    6. Harris R,
    7. Hersey P
    : Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects. Br J Cancer 47(1): 123-133, 1983.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Weidmann E,
    2. Bergmann L,
    3. Stock J,
    4. Kirsten R,
    5. Mitrou PS
    : Rapid cytokine release in cancer patients treated with interleukin-2. J Immunother 12(2): 123-131, 1992.
    OpenUrl
  6. ↵
    1. Oda K,
    2. Kitano H
    : A comprehensive map of the toll-like receptor signaling network. Mol Syst Biol 18(2): 2006.0015, 2006.
  7. ↵
    1. Dummer W,
    2. Becker JC,
    3. Schwaaf A,
    4. Leverkus M,
    5. Moll T,
    6. Bröcker EB
    : Elevated serum levels of interleukin-10 in patients with metastatic melanoma. Melanoma Res 5(1): 67-68, 1995.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Lázár-Molnár E,
    2. Hegyesi H,
    3. Tóth S,
    4. Falus A
    : Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 12(6): 547-554, 2000.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Breslow A
    : Prognostic factors in the treatment of cutaneous melanoma. J Cutan Pathol 6(3): 208-212, 1979.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Abbasi NR,
    2. Shaw HM,
    3. Rigel DS,
    4. Friedman RJ,
    5. McCarthy WH,
    6. Osman I,
    7. Kopf AW,
    8. Polsky D
    : Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA 292(22): 2771-2776, 2004.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Kucera R,
    2. Treskova I,
    3. Vrzalova J,
    4. Svobodova S,
    5. Topolcan O,
    6. Fuchsova R,
    7. Rousarova M,
    8. Treska V,
    9. Kydlicek T
    : Evaluation of IGF1 serum levels in malignant melanoma and healthy subjects. Anticancer Res 34(9): 5217-5220, 2014.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Gaffen SL,
    2. Liu KD
    : Overview of interleukin-2 function, production and clinical applications. Cytokine 28(3): 109-123, 2004.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Rosenberg SA
    : IL-2: the first effective immunotherapy for human cancer. J Immunol 192(12): 5451-5458, 2014.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Gerber SA,
    2. Sorensen EW,
    3. Sedlacek AL,
    4. Lim JY,
    5. Skrombolas D,
    6. Frelinger JG,
    7. Lord EM
    : Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy. Immunology 138(3): 280-292, 2013.
    OpenUrlPubMed
  15. ↵
    1. Forones NM,
    2. Mandowsky SV,
    3. Lourenço LG
    : Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer. Hepatogastroenterology 48(40): 1199-1201, 2001.
    OpenUrlPubMed
  16. ↵
    1. Orditura M,
    2. Romano C,
    3. De Vita F,
    4. Galizia G,
    5. Lieto E,
    6. Infusino S,
    7. De Cataldis G,
    8. Catalano G
    : Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival. Cancer Immunol Immunother 49(10): 530-536, 2000.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Rath T,
    2. Billmeier U,
    3. Waldner MJ,
    4. Atreya R,
    5. Neurath MF
    : From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 30(1): 1461-1465, 2015.
    OpenUrl
  18. ↵
    1. Li Y,
    2. de Haar C,
    3. Chen M,
    4. Deuring J,
    5. Gerrits MM,
    6. Smits R,
    7. Xia B,
    8. Kuipers EJ,
    9. van der Woude CJ
    : Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 59(2): 227-235, 2010.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Yurkovetsky ZR,
    2. Kirkwood JM,
    3. Edington HD,
    4. Marrangoni AM,
    5. Velikokhatnaya L,
    6. Winans MT,
    7. Gorelik E,
    8. Lokshin AE
    : Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 13(8): 2422-2428, 2007.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Mashiah J,
    2. Brenner S,
    3. Pessach Y,
    4. Barak V,
    5. Schachter J
    : Differences in cytokine levels in melanoma patients with and without redness (Brenner sign). Anticancer Res 29(5): 1793-1796, 2009.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Tas F,
    2. Oguz H,
    3. Argon A,
    4. Duranyildiz D,
    5. Camlica H,
    6. Yasasever V,
    7. Topuz E
    : The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma. Med Oncol 22(3): 241-246, 2005.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Hoejberg L,
    2. Bastholt L,
    3. Johansen JS,
    4. Christensen IJ,
    5. Gehl J,
    6. Schmidt H
    : Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. Melanoma Res 22(4): 287-293, 2012.
    OpenUrlPubMed
  23. ↵
    1. Soubrane C,
    2. Rixe O,
    3. Meric JB,
    4. Khayat D,
    5. Mouawad R
    : Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study. Melanoma Res 15(3): 199-204, 2005.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Sanmamed MF,
    2. Carranza-Rua O,
    3. Alfaro C,
    4. Oñate C,
    5. Martín-Algarra S,
    6. Perez G,
    7. Landazuri SF,
    8. Gonzalez A,
    9. Gross S,
    10. Rodriguez I,
    11. Muñoz-Calleja C,
    12. Rodríguez-Ruiz M,
    13. Sangro B,
    14. López-Picazo JM,
    15. Rizzo M,
    16. Mazzolini G,
    17. Pascual JI,
    18. Andueza MP,
    19. Perez-Gracia JL,
    20. Melero I
    : Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins. Clin Cancer Res 20(22): 5697-5707, 2014.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Lattanzio L,
    2. Tonissi F,
    3. Torta I,
    4. Gianello L,
    5. Russi E,
    6. Milano G,
    7. Merlano M,
    8. Lo Nigro C
    : Role of IL-8 induced angiogenesis in uveal melanoma. Invest New Drugs 31(5): 1107-1111, 2013.
    OpenUrlPubMed
  26. ↵
    1. Zhang H,
    2. Fu T,
    3. McGettigan S,
    4. Kumar S,
    5. Liu S,
    6. Speicher D,
    7. Schuchter L,
    8. Xu X
    : IL-8 and cathepsin B as melanoma serum biomarkers. Int J Mol Sci 12(3): 1505-1518, 2011.
    OpenUrlPubMed
  27. ↵
    1. Dennis KL,
    2. Blatner NR,
    3. Gounari F,
    4. Khazaie K
    : Current status of interleukin-10 and regulatory T-cells in cancer. Curr Opin Oncol 25(6): 637-645, 2013.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Guida M,
    2. Riccobon A,
    3. Biasco G,
    4. Ravaioli A,
    5. Casamassima A,
    6. Freschi A,
    7. Palma MD,
    8. Galligioni E,
    9. Nortilli R,
    10. Chiarion-Sileni V,
    11. Picozzo J,
    12. Romanini A,
    13. Nanni O,
    14. Ridolfi R
    : Italian Melanoma Intergroup (IMI). Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy an biochemotherapy in metastatic melanoma. Melanoma Res 16(4): 317-323, 2006.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Torisu-Itakura H,
    2. Lee JH,
    3. Huynh Y,
    4. Ye X,
    5. Essner R,
    6. Morton DL
    : Monocyte-derived IL-10 expression predicts prognosis of stage IV melanoma patients. J Immunother 30(8): 831-838, 2007.
    OpenUrlCrossRef
  30. ↵
    1. Mahipal A,
    2. Terai M,
    3. Berd D,
    4. Chervoneva I,
    5. Patel K,
    6. Mastrangelo MJ,
    7. Sato T
    : Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer Immunol Immunother 60(7): 1039-1045, 2011.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top

In this issue

Anticancer Research: 35 (6)
Anticancer Research
Vol. 35, Issue 6
June 2015
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation of IL-2, IL-6, IL-8 and IL-10 in Malignant Melanoma Diagnostics
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
5 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Evaluation of IL-2, IL-6, IL-8 and IL-10 in Malignant Melanoma Diagnostics
RADEK KUCERA, ONDREJ TOPOLCAN, INKA TRESKOVA, JUDITA KINKOROVA, JINDRA WINDRICHOVA, RADKA FUCHSOVA, SARKA SVOBODOVA, VLADISLAV TRESKA, VACLAV BABUSKA, JAROSLAV NOVAK, JIRI SMEJKAL
Anticancer Research Jun 2015, 35 (6) 3537-3541;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Evaluation of IL-2, IL-6, IL-8 and IL-10 in Malignant Melanoma Diagnostics
RADEK KUCERA, ONDREJ TOPOLCAN, INKA TRESKOVA, JUDITA KINKOROVA, JINDRA WINDRICHOVA, RADKA FUCHSOVA, SARKA SVOBODOVA, VLADISLAV TRESKA, VACLAV BABUSKA, JAROSLAV NOVAK, JIRI SMEJKAL
Anticancer Research Jun 2015, 35 (6) 3537-3541;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • Genetic Variants of the IL2 Gene Related to Risk and Survival in Patients With Colorectal Cancer
  • Adipocytes sensitize melanoma cells to environmental TGF-{beta} cues by repressing the expression of miR-211
  • Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study
  • Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100{beta}
  • Google Scholar

More in this TOC Section

  • Retrospective Study of Radiotherapy Impact on the Outcome of Material-assisted Implant-based Subpectoral Breast Reconstruction
  • Carbon-ion Radiotherapy for Oligometastatic Colorectal Cancer in the Liver or Lung
  • Treatment Volume, Dose Prescription and Delivery Techniques for Dose-intensification in Rectal Cancer: A National Survey
Show more Clinical Studies

Similar Articles

Keywords

  • melanoma
  • interleukin
  • sentinel node
  • Breslow score
Anticancer Research

© 2021 Anticancer Research

Powered by HighWire